Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Portal St. Lucia.
Press releases published on September 3, 2025

تتعاون شركة Synopsis مع Telnyx لطرح تقنيات اتصالات قابلة للتوسع وVoice AI في منطقة الشرق الأوسط وشمال إفريقيا
AUSTIN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- أعلنت Telnyx، المنصة المتكاملة للذكاء الاصطناعي الحواري التي تدعم الاتصالات العالمية، عن عقد شراكة جديدة مع Synopsis، الموزع الرائد للتكنولوجيا في أسواق الشرق الأوسط وإفريقيا. سيفتح هذا التعاون آفاقًا جديدةً …

Breckenridge Distillery Expands California Distribution with Winebow
BRECKENRIDGE, Colo., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), has announced a strategic change in its California distribution …

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an …

Climb Channel Solutions Announces North American Distribution Partnership with Forcepoint to Deliver Data Security Everywhere
EATONTOWN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) announces North American Distribution Partnership with …

TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, …

Istios Health Partners with Infectious Diseases Associates of Central Virginia
PHOENIX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Istios Health, a healthcare technology company transforming infectious disease (ID) and related care through integrated clinical services, real-world data, and research-enabled networks, today announced a …

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the …

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its …

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose …

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that …

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim …

XORTX Initiates IND Preparation for XORLO™ in Gout Program
CALGARY, Alberta, Sept. 03, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …

Mintland Launches to Democratize Real Estate Investing Through Blockchain
Dubai, UAE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mintland, an innovative blockchain-powered platform, has officially launched with the mission to make real estate investing accessible to everyone, regardless of income level or location. By tokenizing premium …

SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride
Breakthrough findings open doors to multi-billion-dollar infection-control markets SALT LAKE CITY, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in …

Synopsis and Telnyx Partner to Deliver Scalable Communications and Voice AI Across MENA
AUSTIN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Telnyx, the full-stack conversational AI platform powering global communications, is proud to announce a new partnership with Synopsis, a leading technology distributor in the Middle East and Africa (MEA). This …

Een veerkrachtige onderneming bouwen die hoge beschikbaarheid combineert met noodherstel
Amsterdam, Nederland. September 2025 - Sean Tilley, EMEA Sales Director bij 11:11 Systems, een leverancier van beheerde infrastructuuroplossingen, deelt zijn inzichten over hoe bedrijven hun bedrijfskritische workloads kunnen moderniseren en beschermen met …

Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for August 2025 of its Virtune Crypto Altcoin Index ETP
Stockholm, 3rd of August 2025 – Virtune AB (Publ) ("Virtune") today announces that it has completed the monthly rebalancing of the Virtune Crypto Altcoin Index ETP, listed on Nasdaq Stockholm and Nasdaq Helsinki (ISIN code SE0023260716). In addition to the …

Virtune AB (Publ) ("Virtune") har genomfört den månatliga rebalanseringen för augusti 2025 av Virtune Crypto Altcoin Index ETP
Stockholm, 3 augusti 2025 – Virtune meddelar idag att man har slutfört den månatliga rebalanseringen av Virtune Crypto Altcoin Index ETP, noterad på Nasdaq Stockholm och Nasdaq Helsinki (ISIN-kod SE0023260716). Utöver Virtune Crypto Altcoin Index ETP …

Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that Gordon Ringold, PhD has …